Vyvanse vs Adderall XR: Head-to-Head Efficacy Compared

What Are Vyvanse and Adderall XR?

Vyvanse (lisdexamfetamine dimesylate) and Adderall XR (mixed amphetamine salts, extended release) are both Schedule II CNS stimulants approved by the FDA for attention-deficit/hyperactivity disorder in children aged 6 and older and in adults. Despite delivering amphetamine to the brain, they differ in chemical structure, delivery mechanism, and pharmacokinetic profile in clinically meaningful ways.

Mechanism of Action

Adderall XR releases a mixture of amphetamine salts (75% d-amphetamine, 25% l-amphetamine) via a beaded dual-release capsule, producing an initial release at ingestion and a second release roughly 4 hours later. The result is a bimodal plasma curve with a first peak around 3 hours and a second peak around 7 hours post-dose [1].

Vyvanse is a prodrug. Lisdexamfetamine itself is pharmacologically inactive. After oral ingestion, it is cleaved by peptidases in the small intestine and red blood cells to release d-lysine and active d-amphetamine [2]. This enzymatic conversion creates a smooth, single-peak plasma curve that peaks at approximately 3.8 hours and sustains therapeutic concentrations for 10 to 14 hours [3].

Why the Delivery Difference Matters

Because Vyvanse requires enzymatic cleavage for activation, intranasal or intravenous misuse yields little additional amphetamine exposure compared to oral dosing. A human pharmacology study showed that intranasal lisdexamfetamine produced similar d-amphetamine Cmax to oral administration, in contrast to the significantly higher Cmax achieved by intranasal d-amphetamine alone [4]. This is the pharmacologic basis for its lower misuse-by-route profile, though it remains a Schedule II substance with substantial abuse potential if swallowed in excess.

FDA Approval and Labeled Indications

Adderall XR received FDA approval in October 2001 for ADHD in pediatric and adult patients [5]. Vyvanse received FDA approval in February 2007 for ADHD and later in January 2015 for moderate-to-severe binge eating disorder (BED) in adults [6]. Neither agent is FDA-approved for cognitive enhancement in people without a diagnosed condition.

The FDA's approved labeling for both drugs includes a boxed warning stating that amphetamines have a high potential for abuse and dependence, and that misuse may cause sudden death and serious cardiovascular adverse events [5, 6].

Efficacy Evidence: What the Trials Show

No published large-scale, double-blind, randomized controlled trial has placed Vyvanse and Adderall XR in the same study arm. Comparing them requires examining separate placebo-controlled trials and one cross-trial perspective.

Vyvanse Key Trials

The Phase III registration program for lisdexamfetamine in adults with ADHD (Biederman et al., J Clin Psychiatry 2007, N=420) showed a mean reduction of 18.6 points on the ADHD Rating Scale IV (ADHD-RS-IV) for lisdexamfetamine 70 mg versus 5.0 points for placebo (P<0.001) [7]. All three doses tested (30 mg, 50 mg, 70 mg) separated from placebo at week 4.

In the pediatric population (Biederman et al., Pediatrics 2007, N=290), lisdexamfetamine 30 to 70 mg reduced ADHD-RS-IV scores by 18.7 to 21.8 points versus 8.1 points for placebo (P<0.001 for all doses) [8].

Adderall XR Key Trials

The original registration trial for Adderall XR (Biederman et al., Pediatrics 2002, N=584 children aged 6 to 12) demonstrated statistically significant ADHD-RS improvements versus placebo across doses of 10 mg, 20 mg, and 30 mg at week 3 [9]. The adult ADHD trial (Spencer et al., Biol Psychiatry 2005, N=255) showed ADHD-RS reductions of approximately 14 to 17 points on active drug versus 6 points on placebo [10].

The Wigal Analog Classroom Study

Wigal et al. (J Atten Disord 2017, comparing lisdexamfetamine and OROS methylphenidate in an analog classroom setting) demonstrated that lisdexamfetamine produced sustained and statistically significant improvements in attention and behavior from 2 hours through 13 hours post-dose in children with ADHD [11]. While this trial does not compare lisdexamfetamine directly to Adderall XR, it establishes the 13-hour behavioral efficacy window that is frequently cited in favor of Vyvanse for afternoon and evening coverage.

The MTA Cooperative Group Study

The landmark Multimodal Treatment Study of Children with ADHD (MTA, N=579, Arch Gen Psychiatry 1999) showed that carefully titrated stimulant medication alone was superior to behavioral therapy alone for core ADHD symptoms, and that combined treatment produced the greatest improvement in non-ADHD outcomes such as academic achievement and social skills [12]. The MTA study used immediate-release methylphenidate as the stimulant agent, not amphetamine salts, but it remains the foundational evidence establishing medication management as the anchor of ADHD treatment.

As the MTA Cooperative Group reported, "Medication management was significantly superior to behavioral treatment and to community care" for core ADHD symptom reduction at 14 months [12].

Cross-Trial Symptom Score Comparison

Placing the registration data side by side is informative but requires caution. Populations, rater training, and baseline severity differ across trials. With that caveat, both drugs produce ADHD-RS-IV reductions in the 14 to 22 point range versus placebo baselines of 30 to 36, translating to approximately 50 to 60% symptom reduction from baseline on active drug [7, 8, 9, 10]. Neither drug consistently outperforms the other on this metric in separate trials.

Duration of Action

Duration of action is one of the most clinically consequential differences between the two drugs.

Adderall XR Duration Profile

Adderall XR's bimodal release produces therapeutic effect from roughly 1 hour post-dose through 8 to 12 hours. The package insert states that behavioral effects extend up to 10 hours in laboratory classroom studies [5]. Some patients report a pronounced "rebound" effect as the drug wears off, characterized by irritability, increased appetite, or fatigue, coinciding with the falling second plasma peak.

Vyvanse Duration Profile

Because lisdexamfetamine's conversion to active d-amphetamine is rate-limited by enzymatic cleavage, the plasma curve is smoother. Peak d-amphetamine concentration (Cmax) occurs at approximately 3.8 hours, and the curve descends more gradually than Adderall XR's bimodal pattern [3]. The Wigal et al. Analog classroom data confirmed significant behavioral effects through hour 13 post-dose [11]. Rebound complaints appear less frequently in clinical reports, though head-to-head rebound data from a controlled trial are not available.

Onset of Action

Speed of onset matters for patients who need to be functional within 30 to 45 minutes of waking.

Adderall XR's immediate-release bead fraction produces measurable CNS effect within 30 to 60 minutes of ingestion [5]. Vyvanse requires enzymatic conversion before any active amphetamine enters systemic circulation; the onset is approximately 60 to 90 minutes and can be delayed by high-fat meals, which slow gastric emptying and thus lisdexamfetamine absorption [6]. Patients who must perform demanding cognitive work in the first hour of the workday may find Adderall XR's faster onset preferable.

Abuse and Misuse Potential

Both drugs carry Schedule II classification under the Controlled Substances Act, meaning the DEA recognizes high potential for abuse and severe psychological or physical dependence [13].

Pharmacokinetic Abuse Deterrence of Vyvanse

The prodrug design of lisdexamfetamine provides pharmacokinetic (not physical) abuse deterrence. Because enzymatic cleavage is required for activation, snorting or injecting lisdexamfetamine does not meaningfully increase the speed or magnitude of d-amphetamine delivery compared to swallowing the capsule [4]. This characteristic led the FDA to note in its review documents that lisdexamfetamine "may have reduced abuse liability compared to immediate-release amphetamine formulations" [6].

Real-World Abuse Rates

A 2016 analysis using the National Survey on Drug Use and Health found that among nonmedical users of prescription stimulants, approximately 60% reported obtaining them from friends or family who had legitimate prescriptions, a figure that applies to both drug classes [14]. Neither Vyvanse nor Adderall XR eliminates diversion risk.

Cardiovascular Risk and Abuse

Both drugs share the same boxed warning. Abuse of either drug, defined as taking higher doses than prescribed or using them without a prescription, substantially raises the risk of tachycardia, hypertension, arrhythmia, and in rare cases sudden cardiac death, particularly in patients with undiagnosed structural cardiac abnormalities [5, 6].

Side Effect Profiles

The adverse-event profiles of both drugs overlap considerably because both ultimately deliver d-amphetamine to the brain.

Shared Side Effects

Common adverse effects seen in registration trials for both agents include decreased appetite (reported in 22 to 35% of pediatric patients), insomnia (10 to 19%), headache (12 to 26%), abdominal pain (11 to 14%), and increased heart rate [7, 8, 9, 10]. Growth suppression with long-term use in pediatric patients is documented for stimulants as a class, with the MTA follow-up cohort showing approximately 2 cm and 2.7 kg deficits at 3 years compared to non-medicated peers [15].

Differences in Side Effect Experience

Because Vyvanse produces a smoother plasma curve, some patients and clinicians report fewer peak-related side effects such as palpitations and appetite suppression at mid-day, compared to the steeper second-peak exposure with Adderall XR. A 2010 open-label study (Findling et al., J Child Adolesc Psychopharmacol, N=272) found that children switching from mixed amphetamine salts to lisdexamfetamine reported improvements in appetite and sleep that their caregivers attributed to the longer, flatter curve [16]. This was not a blinded comparison, and the study had no placebo arm, so this observation should be weighted accordingly.

Adderall XR may be associated with slightly higher rates of mid-afternoon mood rebound in clinical practice, consistent with the sharper decline from its second plasma peak, but this has not been demonstrated in a controlled trial.

Dosing and Titration

Adderall XR Dosing

Adderall XR is initiated at 5 to 10 mg/day in children and 20 mg/day in adults, titrated in 5 to 10 mg weekly increments to a maximum of 30 mg/day for children and 30 to 60 mg/day for adults, depending on age and response [5]. Capsules may be opened and the beads sprinkled on soft food, which does not alter the pharmacokinetics.

Vyvanse Dosing

Vyvanse is initiated at 20 to 30 mg/day and titrated in 10 to 20 mg weekly increments up to a labeled maximum of 70 mg/day [6]. Capsules may be opened and dissolved in water. The maximum approved dose provides approximately 40 mg of active d-amphetamine equivalents after conversion.

Dose Equivalence

Approximate dose equivalence is frequently requested for clinicians switching patients between the two agents. A commonly referenced conversion (supported by pharmacokinetic modeling but not by a formal equivalence trial) places Vyvanse 30 mg near Adderall XR 10 mg, Vyvanse 50 mg near Adderall XR 20 mg, and Vyvanse 70 mg near Adderall XR 30 mg in terms of d-amphetamine delivery [17]. These are starting-point estimates; individual titration is required.

Switching Between Vyvanse and Adderall XR

Switching is common in clinical practice due to insurance formulary changes, generic availability, or tolerability concerns.

Clinical Considerations for the Switch

When switching from Adderall XR to Vyvanse, onset delay is the primary adjustment patients notice. Advising patients to take Vyvanse 30 to 60 minutes earlier than their previous Adderall XR dose compensates for the slower enzymatic conversion onset [6]. A washout period is not required given both are amphetamine-based stimulants with no pharmacodynamic antagonism.

Switching from Vyvanse to Adderall XR requires attention to the shorter duration. Patients accustomed to 13 hours of Vyvanse coverage may notice symptom breakthrough in the early evening with Adderall XR. Some prescribers add a small afternoon dose of immediate-release amphetamine (5 to 10 mg) to bridge coverage, though this increases total daily amphetamine burden and monitoring obligations.

Insurance and Formulary Factors

Generic amphetamine salts XR (the generic for Adderall XR) has been available since 2009 and typically costs significantly less out-of-pocket than branded Adderall XR. Generic lisdexamfetamine became available in 2023 [18]. For patients without adequate insurance, generic lisdexamfetamine and generic amphetamine salts XR are now both accessible, which changes formulary-based switching decisions.

Who Tends to Do Better on Each Drug

No validated predictive biomarker currently distinguishes Vyvanse responders from Adderall XR responders before a trial. Prescribers typically use clinical history and shared decision-making.

Patients Who May Prefer Vyvanse

Patients with a history of afternoon or evening symptom breakthrough on Adderall XR, those who have experienced significant rebound irritability, individuals with a personal or family history of substance misuse where the prescriber wants a pharmacokinetically abuse-deterrent option, and adults with comorbid binge eating disorder (for which only Vyvanse carries an FDA indication) may benefit from lisdexamfetamine [6, 19].

Patients Who May Prefer Adderall XR

Patients who need rapid onset within the first hour of waking, those who prefer a shorter duration to minimize evening insomnia, patients for whom cost is the primary driver and who are willing to accept the bimodal profile, and individuals who have previously responded well without tolerability issues represent reasonable candidates for Adderall XR or its generic [5].

Cardiovascular Monitoring Requirements

Both drugs require cardiovascular assessment before initiation, including personal and family history of structural cardiac disease, sudden death, or arrhythmia, plus baseline heart rate and blood pressure measurement. The American Heart Association recommends an ECG before starting stimulant therapy in patients with any cardiac history or symptoms, though routine ECG screening in otherwise healthy children is not mandatory per the AHA's 2008 Scientific Statement [20].

Prescribers should recheck blood pressure and heart rate at each dose adjustment and at least every 6 months during maintenance therapy. A resting heart rate above 100 bpm or blood pressure above 130/80 mmHg on treatment warrants re-evaluation of dose or agent.

Pregnancy, Lactation, and Special Populations

Both Vyvanse and Adderall XR are FDA Pregnancy Category X equivalents under the current labeling framework. Amphetamine exposure in the first trimester has been associated with small but statistically significant increases in gastroschisis risk in epidemiological data (OR approximately 2.1 in one case-control analysis) [21]. Both drugs pass into breast milk; the American Academy of Pediatrics advises against stimulant use during lactation.

In adults over age 65, cardiovascular comorbidities increase risk, and stimulants are used with particular caution. No registrational trial enrolled patients older than 65 for ADHD.

Key Takeaways for Prescribers and Patients

Vyvanse and Adderall XR are both effective, evidence-supported treatments for ADHD. The absence of a head-to-head randomized trial means that the choice between them rests on pharmacokinetic differences, tolerability history, duration requirements, and practical factors like cost and formulary access rather than on proven superiority of one agent over the other.

Titrate each patient individually using validated outcome measures such as the ADHD-RS-IV or the Conners 3 at each visit. Target the lowest effective dose that controls symptoms without intolerable side effects.